67
Participants
Start Date
April 6, 2018
Primary Completion Date
November 14, 2022
Study Completion Date
November 14, 2022
Midostaurin
Midostaurin 50 mg \[two 25 mg capsules\] were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
Placebo
Placebo, two capsules, were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
Novartis Investigative Site, Taipei
Novartis Investigative Site, Taoyuan District
Novartis Investigative Site, Putzu City
Novartis Investigative Site, Kaohsiung City
Novartis Investigative Site, Hanoi
Novartis Investigative Site, Moscow
Novartis Investigative Site, Moscow
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Pokfulam
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Toyoake
Novartis Investigative Site, Kashiwa
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukushima
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Isehara
Novartis Investigative Site, Nagasaki
Novartis Investigative Site, Okayama
Novartis Investigative Site, Osaka
Novartis Investigative Site, Ōsaka-sayama
Novartis Investigative Site, Hamamatsu
Novartis Investigative Site, Shimotsuke
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Bunkyo-ku
Novartis Investigative Site, Shinagawa Ku
Novartis Investigative Site, Aomori
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Kochi
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Osaka
Novartis Investigative Site, Yamagata
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY